|Title:||Chemotherapy agents induce tartrate-resistant acid phosphatase 5a contributing to the symptom distress in lung cancer patients||Authors:||Chou H.-L.
|Keywords:||Chemotherapy drugs; Lung cancer; Monocyte-differentiated macrophages; Symptom distress; TRACP5a||Issue Date:||2019||Journal Volume:||846||Start page/Pages:||38-48||Source:||European Journal of Pharmacology||Abstract:||
Tartrate-resistant acid phosphatase 5a (TRACP5a) is mainly secreted by activated macrophages in chronic inflammation. Serum TRACP5a is associated with symptom distress in lung cancer patients during chemotherapy. Therefore, this study aimed to investigate whether chemotherapy drugs modulate TRACP5a as an inducible marker for symptom distress in lung cancer patients during chemotherapy. In clinical analysis, lung cancer participants completely received the six-cycle chemotherapy process (n = 42). Clinical determinations for TRACP5a, C-reactive protein (CRP), interleukin-6 (IL-6), white blood cells, monocytes, and hemoglobin were analyzed at six time points: BL, C1d8, C2d1, C4d1, C4d8, and Ed28. Meanwhile, five questionnaires for fatigue, sleep disturbance, pain, depression, and confusion were finished before drug treatment. For monocyte-to-macrophage differentiation, THP-1 cells were treated with phorbol 12-myristate 13-acetate (PMA). TRACP5a secretion in THP-1 cells was determined at the following days up to 6 days after 1-day incubation of chemotherapy drugs by dot blotting. Clinical analysis revealed that TRACP5a significantly increased at C1d8 and C4d8, but dropped at C2d1 and Ed28. CRP and IL-6 displayed a broad-range variation, resulting in no significant difference among the assessment time points. In contrast, monocytes decreased at C1d8 and C4d8, but rose again at C2d1 and Ed28. In symptom distress, the changes only in fatigue and sleep disturbance were positively associated with the trend in TRACP5a. In PMA-treated THP-1 cells, TRACP5a significantly increased after stimulation with gemcitabine and paclitaxel. Taken together, induction of TRACP5a by chemotherapy drugs might be generated from monocyte-differentiated macrophages, further causing clinical symptom distress in lung cancer patients. ? 2019 Elsevier B.V.
|URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/502641||ISSN:||0014-2999||DOI:||10.1016/j.ejphar.2019.01.011||SDG/Keyword:||acid phosphatase tartrate resistant isoenzyme; C reactive protein; carboplatin; cisplatin; gemcitabine; hemoglobin; interleukin 6; paclitaxel; phorbol 13 acetate 12 myristate; tartrate resistant acid phosphatase 5a; unclassified drug; vinorelbine tartrate; acid phosphatase tartrate resistant isoenzyme; antineoplastic agent; biological marker; C reactive protein; hemoglobin; interleukin 6; phorbol 13 acetate 12 myristate; adult; Article; cancer chemotherapy; cancer patient; cell differentiation; clinical article; confusion; controlled study; depression; dot blotting; drug effect; fatigue; female; hemoglobin blood level; human; in vitro study; incubation time; leukocyte; leukocyte count; macrophage; male; mental stress; monocyte; multiple cycle treatment; non small cell lung cancer; pain; priority journal; protein analysis; protein blood level; protein expression; questionnaire; sleep disorder; THP-1 cell line; time factor; aged; blood; chemically induced; lung tumor; metabolism; middle aged; non small cell lung cancer; pathophysiology; psychology; symptom assessment; Aged; Antineoplastic Agents; Biomarkers; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Confusion; Depression; Fatigue; Female; Hemoglobins; Humans; Interleukin-6; Leukocytes; Lung Neoplasms; Macrophages; Male; Middle Aged; Monocytes; Sleep Wake Disorders; Symptom Assessment; Tartrate-Resistant Acid Phosphatase; Tetradecanoylphorbol Acetate; THP-1 Cells
|Appears in Collections:||醫學檢驗暨生物技術學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.